-transparent.png){kind=logo}
A combination of sulbactam, a beta-lactamase inhibitor, plus cefoperazone (SBT/CPZ = 1/1) was studied in the field of obstetrics and gynecology, and the results were following: Absorption and transfer into genital organ tissues were good. With the 1g intravenous injection the maximum serum concentrations in the uterine artery were 88.6 micrograms/ml for CPZ and 50.0 micrograms/ml for SBT, and the maximum tissue concentrations were 12.2-17.4 micrograms/g for CPZ and 9.8-21.4 micrograms/g for SBT. When the 2 g was administered, the maximum tissue concentrations were 11.9-26.7 micrograms/g for CPZ and 6.0-8.0 micrograms/g for SBT. These elimination showed the similar trend as their serum levels, and their tissue levels were higher than MIC80 for the main organisms. Their penetration into the intrapelvic dead space exudate was also good and showed that the peak levels were 30.1 micrograms/ml for CPZ and 17.4 micrograms/ml for SBT at 2 hours after the 2 g intravenous injection. The peak levels of 34.4 micrograms/ml for CPZ and 8.8 micrograms/ml for SBT at 6 hours after 2 g intravenous drip infusion were obtained. Their elimination was slow, and the concentration higher than MIC80 for main organisms was maintained for a long period of time. For gyneco-obstetrical infections such as adnexitis, intrauterine, intrapelvic and external genital organ infections, a daily dose of 2-4 g of SBT/CPZ produced a 100% clinical efficacy in 10 patients and a 88.9% bacteriological effect. The eradication ratio was more than 80% against beta-lactamase producing organisms. Side effects were few. The above results indicated that SBT/CPZ was useful in the field of obstetrics and gynecology.
N Cho, and
H Watanabe, and
K Yoshida, and
S Moriyama, and
H Takeda, and
A Tsukamoto, and
K Fukunaga, and
K Kunii
November 1984,
The Japanese journal of antibiotics,
N Cho, and
H Watanabe, and
K Yoshida, and
S Moriyama, and
H Takeda, and
A Tsukamoto, and
K Fukunaga, and
K Kunii
November 1984,
The Japanese journal of antibiotics,
N Cho, and
H Watanabe, and
K Yoshida, and
S Moriyama, and
H Takeda, and
A Tsukamoto, and
K Fukunaga, and
K Kunii
October 1984,
The Japanese journal of antibiotics,
N Cho, and
H Watanabe, and
K Yoshida, and
S Moriyama, and
H Takeda, and
A Tsukamoto, and
K Fukunaga, and
K Kunii
November 1984,
The Japanese journal of antibiotics,
N Cho, and
H Watanabe, and
K Yoshida, and
S Moriyama, and
H Takeda, and
A Tsukamoto, and
K Fukunaga, and
K Kunii
November 1984,
The Japanese journal of antibiotics,
N Cho, and
H Watanabe, and
K Yoshida, and
S Moriyama, and
H Takeda, and
A Tsukamoto, and
K Fukunaga, and
K Kunii
November 1984,
The Japanese journal of antibiotics,
N Cho, and
H Watanabe, and
K Yoshida, and
S Moriyama, and
H Takeda, and
A Tsukamoto, and
K Fukunaga, and
K Kunii
November 1984,
The Japanese journal of antibiotics,
N Cho, and
H Watanabe, and
K Yoshida, and
S Moriyama, and
H Takeda, and
A Tsukamoto, and
K Fukunaga, and
K Kunii
December 1984,
The Japanese journal of antibiotics,
N Cho, and
H Watanabe, and
K Yoshida, and
S Moriyama, and
H Takeda, and
A Tsukamoto, and
K Fukunaga, and
K Kunii
November 1984,
The Japanese journal of antibiotics,
N Cho, and
H Watanabe, and
K Yoshida, and
S Moriyama, and
H Takeda, and
A Tsukamoto, and
K Fukunaga, and
K Kunii
November 1984,
The Japanese journal of antibiotics,
